Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Other Non-Current Assets (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Other Non-Current Assets data on record, last reported at $16.5 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 117721.43% to $16.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $16.5 million, a 117721.43% increase, with the full-year FY2025 number at $16.8 million, up 50.39% from a year prior.
  • Other Non-Current Assets reached $16.5 million in Q1 2026 per OLMA's latest filing, down from $16.8 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for OLMA hit a ceiling of $16.8 million in Q4 2025 and a floor of $14000.0 in Q1 2025.
  • A 5-year average of $6.8 million and a median of $4.3 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: plummeted 99.86% in 2025, then soared 117721.43% in 2026.
  • Tracing OLMA's Other Non-Current Assets over 5 years: stood at $4.3 million in 2022, then surged by 91.51% to $8.1 million in 2023, then skyrocketed by 37.48% to $11.2 million in 2024, then surged by 50.39% to $16.8 million in 2025, then dropped by 2.0% to $16.5 million in 2026.
  • Business Quant data shows Other Non-Current Assets for OLMA at $16.5 million in Q1 2026, $16.8 million in Q4 2025, and $16.7 million in Q3 2025.